DDW’s Megan Thomas caught up with Philipp Baaske, Co-Founder & Executive Chairman of NanoTemper Technologies, about biophysical characterisation techniques for complex biologics.

Highlights of the Vodcast

As drug discovery moves beyond traditional small molecules, biophysical characterisation techniques must evolve to keep pace with the increasing complexity of new drug modalities. Dr Baaske used the analogy: “If aspirin has the complexity of a bike, an antibody has the complexity of an airplane… a big one.” To handle this complexity, Baaske advocates for a master multiplexing optical methods (MOM) approach, where multiple biophysical analysis techniques are combined into a single device. “The idea is to give you the full picture of your sample with one shot by combining different biophysical methods,” he explained. “This will be the key for the next decade.”

Overcoming obstacles

Baaske answers the question of the sector’s challenges: “The biggest challenges are political madness and lack of funding.” He suggests that if we invest more resources into science than weapons, it will be possible to find new medicines faster and reduce the costs of the drug therapies.
Baaske sees this mismatch in priorities as a waste of “so many bright minds” working to cure cancer despite the lack of funding and resources.
One persistent challenge in drug discovery is identifying and mitigating protein aggregation early in the development process. Baaske explains that the current focus is on simply detecting the presence of aggregates, but he believes the field needs to go further.
By using a combination of biophysical techniques, researchers can not only detect aggregation, but also understand the underlying causes, whether it’s native-state aggregation or unfolding-induced aggregation.

Integrating AI and biophysical analysis

Baaske envisions a future where AI and biophysical methods work in harmony, creating a lab-in-the-loop where experimental data trains predictive models, which then inform the next round of experiments.

“If you have the strongest training set, you will be first on the market. I think we will see a golden age of biophysics coming,” Baaske said, emphasising the importance of pharmaceutical companies owning their own AI training datasets.

Label-free biophysical methods

“There will be no future of drug discovery without biophysical methods”, says Baaske. He considers biophysics to be an engineering discipline with protein architects, designers, engineers, testers, and producers all working together. He says that the ability to obtain real, absolute biophysical data to define references and industrial standards will be a crucial catalyst for the industry.

Balancing efficiency and decision-making

As biophysical techniques generate ever-increasing amounts of data, the challenge becomes interpreting and applying that information effectively. Baaske acknowledges this as an ‘art’ that the industry has yet to master.

Baaske believes AI can help bridge this gap by enhancing the user interface and creating a more “conversational style” between researchers and their biophysical instruments. The goal is for these tools to become companions that can translate the user’s needs into the appropriate data analysis and experimental planning.

Looking forward

Baaske’s personal experiences with cancer in his family motivated him to found NanoTemper in 2008, with the goal of developing biophysical methods that could measure small molecules, which had previously been a challenge. But the potential in this field expands far beyond this personal motivation.
Baaske says he is excited about NanoTemper’s pipeline of R&D projects, with a focus on further automating lab processes to create a true lab-in-the-loop. The goal is to combine more technologies into a single device to provide a more comprehensive biophysical analysis, including information on binding stoichiometry.

Baaske hopes NanoTemper’s devices will become standard tools that allow scientists to focus on the creative aspects of drug design and problem-solving. He hopes that while devices from NanoTemper do its job, scientists can focus on designing the next drug. “This is my dream,” he concludes.